• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

    0.5597 UNCHANGED
    Last Price Updated: 4:00 PM EST, Dec 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.5597
    Bid (Size) 0.5500 (14)
    Ask (Size) 0.5800 (7)
    Prev. Close 0.5597
    Today's Range 0.5597 - 0.5597
    52wk Range 0.5597 - 19.90
    Shares Outstanding 4,063,081
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Biora Therapeutics (BIOR) Stock Is Down 45%
    Biora Therapeutics shares are trading lower by 45% during Tuesday's session. The company announced that it will be delisted from Nasdaq. 
    Via Benzinga

    Performance

    YTD
    -95.79%
    -95.79%
    1 Month
    -66.49%
    -66.49%
    3 Month
    -90.14%
    -90.14%
    6 Month
    -91.89%
    -91.89%
    1 Year
    -95.66%
    -95.66%

    More News

    Read More
    Dow Falls 150 Points; Oracle Posts Downbeat Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics's Earnings Outlook
    Via Benzinga
    Earnings Scheduled For November 14, 2024
    Via Benzinga
    Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics Achieves ISO 13485 Certification
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics Announces Positive Nasdaq Listing Decision
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics Announces Funding Agreement with Existing Investors
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
    From Biora Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.